These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27828878)

  • 1. Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda.
    Koss CA; Natureeba P; Kwarisiima D; Ogena M; Clark TD; Olwoch P; Cohan D; Okiring J; Charlebois ED; Kamya MR; Havlir DV
    J Acquir Immune Defic Syndr; 2017 Mar; 74(3):279-284. PubMed ID: 27828878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.
    Matthews LT; Kaida A; Kanters S; Byakwagamd H; Mocello AR; Muzoora C; Kembabazi A; Haberer JE; Martin JN; Bangsberg DR; Hunt PW
    AIDS; 2013 Oct; 27 Suppl 1(0 1):S105-12. PubMed ID: 24088676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to HIV antiretroviral therapy among pregnant and postpartum women during the Option B+ era: 12-month cohort study in urban South Africa and rural Uganda.
    Matthews LT; Orrell C; Bwana MB; Tsai AC; Psaros C; Asiimwe S; Amanyire G; Musinguzi N; Bell K; Bangsberg DR; Haberer JE;
    J Int AIDS Soc; 2020 Aug; 23(8):e25586. PubMed ID: 32820622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of undetectable and suppressed viral load in HIV-infected pregnant women initiating Option B+ in Uganda: an observational study nested within a randomized controlled trial.
    Gabagaya G; Rukundo G; Amone A; Wavamunno P; Namale-Matovu J; Lubega I; Nakabiito C; Namukwaya Z; Nolan M; Malamba SS; King R; Homsy J; Fowler MG; Musoke P
    BMC Infect Dis; 2021 Sep; 21(1):907. PubMed ID: 34481464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
    Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
    J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of universal antiretroviral therapy for pregnant and postpartum women on antiretroviral therapy uptake and retention.
    Abrams EJ; Langwenya N; Gachuhi A; Zerbe A; Nuwagaba-Biribonwoha H; Mthethwa-Hleta S; Sahabo R; Lesosky M; Okello V; Myer L
    AIDS; 2019 Jan; 33(1):45-54. PubMed ID: 30289804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
    Jain V; Byonanebye DM; Amanyire G; Kwarisiima D; Black D; Kabami J; Chamie G; Clark TD; Rooney JF; Charlebois ED; Kamya MR; Havlir DV;
    AIDS; 2014 Sep; 28(15):2241-9. PubMed ID: 25022596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study.
    Myer L; Dunning L; Lesosky M; Hsiao NY; Phillips T; Petro G; Zerbe A; McIntyre JA; Abrams EJ
    Clin Infect Dis; 2017 Feb; 64(4):422-427. PubMed ID: 27927852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: A randomised controlled trial.
    Myer L; Phillips TK; Zerbe A; Brittain K; Lesosky M; Hsiao NY; Remien RH; Mellins CA; McIntyre JA; Abrams EJ
    PLoS Med; 2018 Mar; 15(3):e1002547. PubMed ID: 29601570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
    Koss CA; Natureeba P; Mwesigwa J; Cohan D; Nzarubara B; Bacchetti P; Horng H; Clark TD; Plenty A; Ruel TD; Achan J; Charlebois ED; Kamya MR; Havlir DV; Gandhi M
    AIDS; 2015 Apr; 29(7):825-30. PubMed ID: 25985404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-uptake of viral load testing among people receiving HIV treatment in Gomba district, rural Uganda.
    Nakalega R; Mukiza N; Kiwanuka G; Makanga-Kakumba R; Menge R; Kataike H; Maena J; Akello C; Atuhaire P; Matovu-Kiweewa F; Ndikuno-Kuteesa C; Debem H; Mujugira A
    BMC Infect Dis; 2020 Oct; 20(1):727. PubMed ID: 33023498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods.
    Matthews LT; Ribaudo HB; Kaida A; Bennett K; Musinguzi N; Siedner MJ; Kabakyenga J; Hunt PW; Martin JN; Boum Y; Haberer JE; Bangsberg DR
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):399-406. PubMed ID: 26495883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Program Implementation of Option B+ at a President's Emergency Plan for AIDS Relief-Supported HIV Clinic Improves Clinical Indicators But Not Retention in Care in Mbarara, Uganda.
    Miller K; Muyindike W; Matthews LT; Kanyesigye M; Siedner MJ
    AIDS Patient Care STDS; 2017 Aug; 31(8):335-341. PubMed ID: 28650703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linkage to care, mobility and retention of HIV-positive postpartum women in antiretroviral therapy services in South Africa.
    Phillips TK; Clouse K; Zerbe A; Orrell C; Abrams EJ; Myer L
    J Int AIDS Soc; 2018 Jul; 21 Suppl 4(Suppl Suppl 4):e25114. PubMed ID: 30027583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
    Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi.
    Tenthani L; Haas AD; Tweya H; Jahn A; van Oosterhout JJ; Chimbwandira F; Chirwa Z; Ng'ambi W; Bakali A; Phiri S; Myer L; Valeri F; Zwahlen M; Wandeler G; Keiser O
    AIDS; 2014 Feb; 28(4):589-598. PubMed ID: 24468999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facilitators and barriers to uptake and adherence to lifelong antiretroviral therapy among HIV infected pregnant women in Uganda: a qualitative study.
    Buregyeya E; Naigino R; Mukose A; Makumbi F; Esiru G; Arinaitwe J; Musinguzi J; Wanyenze RK
    BMC Pregnancy Childbirth; 2017 Mar; 17(1):94. PubMed ID: 28320347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of male partner involvement in ART retention and adherence in Malawi's Option B+ program.
    Wesevich A; Mtande T; Saidi F; Cromwell E; Tweya H; Hosseinipour MC; Hoffman I; Miller WC; Rosenberg NE
    AIDS Care; 2017 Nov; 29(11):1417-1425. PubMed ID: 28355926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probable antenatal depression at antiretroviral initiation and postpartum viral suppression and engagement in care.
    Harrington BJ; Pence BW; Maliwichi M; Jumbe AN; Gondwe NA; Wallie SD; Gaynes BN; Maselko J; Miller WC; Hosseinipour MC;
    AIDS; 2018 Nov; 32(18):2827-2833. PubMed ID: 30234603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.